Matinas biopharma successfully reaches agreement with fda for a single phase 3 registration trial to support an nda for mat2203 for the treatment of invasive aspergillosis

Oralto phase 3 trial focused on desired initial target indication of early oral step-down treatment of invasive aspergillosis infections in adults who have limited or no treatment options

MTNB Ratings Summary

MTNB Quant Ranking